Fibroblast Growth Factor 21 (FGF21) in Human Cerebrospinal Fluid
Relationship With Plasma FGF21 and Body Adiposity
- Bee K. Tan1,2⇓,
- Manfred Hallschmid3,
- Raghu Adya1,
- Werner Kern4,
- Hendrik Lehnert1,4 and
- Harpal S. Randeva1
- 1Endocrinology and Metabolism Group, Clinical Sciences Research Institute, Warwick Medical School, University of Warwick, Coventry, U.K.
- 2Department of Reproductive Medicine and Surgery, Addenbrooke’s Hospital, Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, U.K.
- 3Department of Neuroendocrinology, University of Lübeck, Lübeck, Germany
- 41st Medical Department, University of Lübeck Medical School, Lübeck, Germany
- Corresponding author: Bee K. Tan, .
OBJECTIVE Reports of increased circulating fibroblast growth factor 21 (FGF21) levels in obesity indicate that FGF21 may be implicated in body weight homeostasis. We sought to investigate the existence of FGF21 in human cerebrospinal fluid (CSF) and, if present, the relationship between CSF FGF21 with body adiposity and metabolic parameters.
RESEARCH DESIGN AND METHODS CSF and corresponding plasma FGF21 were measured by an enzyme-linked immunosorbent assay (18 men and 20 women, aged 19–80 years, and BMI 16.2–38.1 kg/m2) and correlated to body adiposity and metabolic parameters.
RESULTS CSF and plasma FGF21 increased in particular with rising BMI and fat mass. In CSF, FGF21 was detectable at concentrations ~40% that of plasma levels. CSF and plasma FGF21 levels were significantly positively correlated with BMI and fat mass, body weight, plasma insulin, and homeostasis model assessment of insulin resistance. Plasma FGF21 levels were significantly negatively correlated with plasma adiponectin. When subjected to multiple regression analysis, only fat mass was predictive of plasma FGF21 (β = 0.758; P = 0.004) and CSF FGF21 (β = 0.767; P = 0.007). The CSF-to-plasma FGF21 ratio was significantly negatively correlated with BMI, fat mass, and plasma FGF21. Subjects in the highest plasma FGF21 quintile had a lower CSF-to-plasma FGF21 ratio (12.7% [9.7–14.9]) compared with those in the lowest plasma FGF21 quintile (94.7% [37.3–99.8]) (P < 0.01).
CONCLUSIONS Our observations have important implications with respect to the potential central actions of FGF21. Future research should seek to clarify whether FGF21 would be beneficial in the management of obesity and its metabolic complications.
- Received May 18, 2011.
- Accepted August 10, 2011.
- © 2011 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.